EUVIMEDEUVIMED entdecken
Open Access

Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study

J W Tijmen van der Wel iD, Mirjam C Boelens, Merel Jebbink iD, Sietske A Smulders, Klaartje W Maas, Merel J A Luitse iD, Annette Compter iD, Robin P B Boltjes, Nik Sol iD, Kim Monkhorst iD, Daan van den Broek iD, Egbert F Smit iD und 2 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von J W Tijmen van der Wel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Dutch Cancer Society, The Dutch Ministry of Health, Welfare and Sport.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to osimertinib in cerebrospinal fluid (CSF) and plasma.

Methods

EGFRm + patients with new or progressive LM during osimertinib were enrolled. NGS Ampliseq was performed on DNA isolated from CSF. Patients were prescribed osimertinib dose escalation (DE, 160 mg QD) following lumbar puncture. Clinical and radiological response was evaluated 4 weeks after osimertinib DE.

Results

Twenty-eight patients were included. The driver mutation was identified in 93% of CSF samples (n = 26). Seven (27%) harbored ≥1 RM. Twenty-five patients (89%) were prescribed osimertinib DE. Four weeks afterwards, symptoms improved in 5 patients, stabilized in 9 and worsened in 11 patients. Twenty-one (84%) patients underwent MR imaging. Four showed radiological improvement, 14 stabilization, and 3 worsening.

Conclusions

In 27% of patients, an RM was found in CSF ctDNA, none of which are targetable at the time of writing, and the clinical efficacy of osimertinib DE seems limited. There is much to gain in diagnostic as well as therapeutic strategies in EGFRm + NSCLC LM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsErbB ReceptorsMutationDrug Resistance, NeoplasmMeningeal CarcinomatosisHumansFemaleMaleMiddle AgedAgedAntineoplastic AgentsMeningeal NeoplasmsAdultAged, 80 and overFollow-Up StudiesPrognosisProtein Kinase InhibitorsIndolesPyrimidines

Stichwörter der Autor:innen

EGFRNSCLCleptomeningeal metastasesosimertinibresistance

Substanzen

osimertinibAniline CompoundsAcrylamidesErbB ReceptorsEGFR protein, humanAntineoplastic AgentsProtein Kinase InhibitorsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Pulmonary Diseases, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
  • Department of Pulmonary Diseases, Haaglanden Medical Center, The Hague, The Netherlands.
  • Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: J W Tijmen van der Wel, Merel Jebbink, Merel J A Luitse, Annette Compter, Nik Sol, Kim Monkhorst, Daan van den Broek, Egbert F Smit, Adrianus J de Langen, Dieta Brandsma

Förderung

  • Dutch Cancer Society
  • The Dutch Ministry of Health, Welfare and Sport

Zitieren

APA

van der Wel, J. W. T., Boelens, M. C., Jebbink, M., Smulders, S. A., Maas, K. W., Luitse, M. J. A., Compter, A., Boltjes, R. P. B., Sol, N., Monkhorst, K., van den Broek, D., Smit, E. F., de Langen, A. J., & Brandsma, D. (2024). Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae138

Vancouver

van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, et al. Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae138

BibTeX
@article{vanderWel2024,
  author = {van der Wel, J W Tijmen and Boelens, Mirjam C and Jebbink, Merel and Smulders, Sietske A and Maas, Klaartje W and Luitse, Merel J A and Compter, Annette and Boltjes, Robin P B and Sol, Nik and Monkhorst, Kim and van den Broek, Daan and Smit, Egbert F and de Langen, Adrianus J and Brandsma, Dieta},
  title = {Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae138}
}
Kostenlos starten →